Thermo Fisher sees Q1 EPS over 20% of full-year total, consensus $5.41

Says clinical research business continues to perform very well. Says starting the year with strong outlook. Says FY23 revenue outlook assumes 7% core organic revenue growth. Sees FY23 adjusted operating margin 23.9%. Says assuming foreign exchange is a year-over-year tailwind of $100M of revenue Sees FY23 tax rate 11%. Sees FY23 capital expenditures $2B. Sees FY23 free cash flow $6.9B. Sees Q1 organic revenue growth mid single digits. Sees Q1 EPS over 20% of full year total. Comments and guidance taken from Q4 earnings conference call.